Gilead released its first quarter earnings and the pharmaceuticals company did not disappoint. However, there is a lot more behind the numbers, especially with their $84,000-a-bottle Sovaldi drug. We spoke with The Street contributor Tim Mullaney on how this particular drug impacted the company’s earnings. Gilead reporting earnings of $1.48 a share on $5 billion in revenues. Sovaldi is estimated to become a $300 billion drug, as there are more than three million American with Hepatitis C.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
